Ignite Creation Date:
2025-12-25 @ 1:43 AM
Ignite Modification Date:
2026-01-02 @ 5:28 AM
Study NCT ID:
NCT06324994
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-03-22
First Post:
2024-03-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.
Sponsor:
Dalian Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-05-01
Start Date Type:
ESTIMATED
Primary Completion Date:
2025-05-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2024-03-09
First Submit QC Date:
None
Study First Post Date:
2024-03-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-15
Last Update Post Date:
2024-03-22
Last Update Post Date Type:
ACTUAL